American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Sacituzumab govitecan and pembrolizumab combination therapy showed promising clinical benefit in early-stage triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

Efficacy and Safety of Camrelizumab, Apatinib, and Chemotherapy as Neoadjuvant Therapy for Stage II-III TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of camrelizumab, apatinib, and chemotherapy shows favorable outcomes in the neoadjuvant setting for stage II-III triple-negative breast cancer (TNBC), particularly in patients with programmed death-ligand 1 positivity. Read More ›

Wrap-Up

Phase 3 Trial of Benmelstobart Plus Anlotinib Versus Nab-Paclitaxel in First-Line Treatment of Recurrent or Metastatic TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of benmelstobart and anlotinib showed a numerical, though not a statistically significant improvement in progression-free survival and overall survival over nab-paclitaxel in recurrent or metastatic triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

Phase 3 ASCENT-04/KEYNOTE-D19 Study: Sacituzumab Govitecan Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab in First-Line, PD-L1–Positive, Advanced TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The ASCENT-04/KEYNOTE-D19 trial highlights sacituzumab govitecan plus pembrolizumab as a promising first-line therapy for patients with programmed death-ligand 1 (PD-L1)-positive, advanced triple-negative breast cancer (TNBC). Read More ›

Phase 3 DeLLphi-304: Primary Analysis of Tarlatamab Versus Chemotherapy as Second-Line Treatment for Patients With SCLC

ASCO 2025 - Small Cell Lung Cancer

The DeLLphi-304 trial shows tarlatamab significantly improves survival with a manageable adverse-event profile over chemotherapy, establishing a new standard of care for patients with small cell lung cancer (SCLC) after platinum-based chemotherapy. Read More ›

A Randomized, Phase 2 Trial Evaluating Atezolizumab Maintenance Therapy Following Chemoradiotherapy in LS-SCLC

ASCO 2025 - Small Cell Lung Cancer

A randomized, phase 2 study found atezolizumab maintenance after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC) did not improve survival outcomes and caused additional toxicities. Read More ›

IMforte Phase 3 Study: Lurbinectedin Plus Atezolizumab Improves Survival in Extensive-Stage Small Cell Lung Cancer

ASCO 2025 - Small Cell Lung Cancer

The IMforte study showed clinically meaningful improvements in progression-free survival and overall survival with lurbinectedin plus atezolizumab compared with atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›

Promising Phase 2 Results for ZG006, a Trispecific T-Cell Engager, in Advanced Small Cell Lung Cancer

ASCO 2025 - Small Cell Lung Cancer

ZG006 demonstrated promising efficacy and a tolerable safety profile in patients with advanced small cell lung cancer, supporting further evaluation in the ongoing phase 2 study. Read More ›

Wrap-Up

MDS/Neoplasms: Time Toxicity for Patients Receiving Oral Versus Parenteral HMAs

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the ASCO 2024 Annual Meeting, researchers presented the differences in time toxicity among patients undergoing myelodysplastic syndromes/neoplasms with oral hypomethylating versus parenteral hypomethylating agents. Read More ›

Wrap-Up

Phase 2 Results From the ASTREON Trial: Preliminary Safety and Efficacy of Oral AZA in Patients With Low-/Intermediate-Risk MDS

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the ASCO 2024 Annual Meeting, researchers presented oral azacitidine’s safety and efficacy results in patients with low-/intermediate-risk myelodysplastic syndromes, as documented in the ASTREON trial. Read More ›

American Society of Clinical Oncology (ASCO)

Page 3 of 33